| Stereochemistry | ABSOLUTE |
| Molecular Formula | C15H18O8 |
| Molecular Weight | 326.2986 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@](O)(C(C)(C)C)[C@]34[C@@H](O)C(=O)O[C@@]3([H])OC(=O)[C@]14CC(=O)O2
InChI
InChIKey=MOLPUWBMSBJXER-YDGSQGCISA-N
InChI=1S/C15H18O8/c1-12(2,3)14(20)4-6-13(5-7(16)21-6)10(19)23-11-15(13,14)8(17)9(18)22-11/h6,8,11,17,20H,4-5H2,1-3H3/t6-,8-,11-,13-,14+,15+/m0/s1
The sesquiterpene trilactone bilobalide is one of the active constituents of the 50:1 Ginkgo biloba leaf extract widely used to enhance memory and learning. Bilobalide was found to antagonise the direct action of gamma-aminobutyric acid (GABA) on recombinant alpha(1)beta(2)gamma(2L) GABA(A) receptors. Bilobalide showed anticonvulsant properties through the activation of glutamic acid decarboxylase (GAD) enzyme, which is a key enzyme in biosynthesis of GABA. Bilobalide has been proposed to exert protective and trophic effects on neurons. Bilobalide may be useful in developing therapy for diseases involving age-associated neurodegeneration. Bilobalide is an active component of EGb, a standardised extract of Ginkgo biloba leaves. Bilobalide accounts for about 3% of the total extract.
CNS Activity
Originator
Approval Year
Sourcing
PubMed
Patents
Sample Use Guides
Oral administration of bilobalide at 3 and 6 mg/kg/day
Route of Administration:
Oral
SUBSTANCE RECORD
